HOT NEWS
Boehringer Ingelheim launches 'Lean-to-Clinic' program for fast drug product sup... » Boehringer Ingelheim has expanded its biopharmaceutical cell line development services and provides ...
43 research talents awarded scholarships to help secure Denmark's future » 43 of Denmark's most talented students in the biotechnological and pharmaceutical sciences will toda...
Novartis drug Signifor® recommended by CHMP for EU approval » The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ado...
Genzyme Announces European Approval of Framingham Manufacturing Plant » Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the European Me...
AstraZeneca and IMS Health announce real-world evidence collaboration in Europe » AstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provi...
MyAsthma App - a New Dimension in Asthma Control » GlaxoSmithKline (GSK) has announced the launch of MyAsthma, the UK's first, free personalised health...
Shire's Venvanse® (lisdexamfetamine dimesylate) Marketing Application accepted ... » Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced...
Bayer's Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Sec... » Bayer HealthCare has submitted an application for marketing authorization to the European Medicines ...
Avastin receives EU approval for the treatment of women with newly diagnosed, ad... » Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Avastin (beva...
First-of-its-Kind Endovascular Trial of the Investigational Esprit(TM) Therapy » Abbott (NYSE: ABT) today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in...
Amgen
AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, please visit http://www.amgen.com

Amgen RSS Channel
Title Filter     Display # 
# Article Title Hits
1 XGEVA® (Denosumab) Granted Marketing Authorization in the European Union 3589
2 Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination with Chemotherapy 5761
3 Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion 6298
4 Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) 6448
5 Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 8202
6 Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial 8662
7 Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union 11161
8 Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union 8711
9 Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards 8962
 
Bookmark and Share